Equities analysts predict that Aerie Pharmaceuticals (NASDAQ:AERI) will report earnings of ($0.89) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Aerie Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.81) and the lowest estimate coming in at ($0.96). Aerie Pharmaceuticals reported earnings per share of ($0.62) during the same quarter last year, which would suggest a negative year-over-year growth rate of 43.5%. The company is scheduled to report its next earnings results on Tuesday, May 1st.
According to Zacks, analysts expect that Aerie Pharmaceuticals will report full year earnings of ($3.57) per share for the current financial year, with EPS estimates ranging from ($3.62) to ($3.52). For the next year, analysts expect that the company will post earnings of ($1.65) per share, with EPS estimates ranging from ($2.15) to ($0.84). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Aerie Pharmaceuticals.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Wednesday, February 28th. The company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.17).
Hedge funds and other institutional investors have recently bought and sold shares of the stock. QS Investors LLC acquired a new position in shares of Aerie Pharmaceuticals during the 4th quarter worth about $125,000. Public Employees Retirement Association of Colorado acquired a new position in shares of Aerie Pharmaceuticals during the 4th quarter worth about $176,000. Great West Life Assurance Co. Can lifted its position in shares of Aerie Pharmaceuticals by 65.0% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock worth $204,000 after purchasing an additional 1,639 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. acquired a new position in shares of Aerie Pharmaceuticals during the 3rd quarter worth about $204,000. Finally, GSA Capital Partners LLP lifted its position in shares of Aerie Pharmaceuticals by 31.3% during the 3rd quarter. GSA Capital Partners LLP now owns 6,444 shares of the company’s stock worth $313,000 after purchasing an additional 1,538 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.
NASDAQ AERI traded down $0.55 on Wednesday, reaching $54.60. The stock had a trading volume of 135,484 shares, compared to its average volume of 349,904. The company has a debt-to-equity ratio of 0.91, a current ratio of 10.09 and a quick ratio of 10.09. Aerie Pharmaceuticals has a 1 year low of $38.14 and a 1 year high of $66.60. The company has a market capitalization of $2,097.07, a P/E ratio of -16.20 and a beta of 0.95.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.